Ulnar Wrist Pain Treatment With Dextrose Prolotherapy
Unknown statusNot applicableNCT03411811
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Participants who have failed therapy for chronic wrist pain on the little finger side of the wrist will recieve dextrose prolotherapy. Their results will be compared to a cohort of consecutive participants who have not failed therapy, and receive 4 weeks of usual care.
Study details
- Official title
- Dextrose Prolotherapy in Chronic Ulnar Wrist Pain Resistant to Usual Care: Comparison to a Naive-to-treatment Cohort Who Receive Usual Care
- Conditions
- Ulnar Wrist Pain
- Interventions
- Other: Usual Care
- Procedure: Dextrose
- Sponsor
- Universidad Abierta Interamericana
- Collaborators
- Gonzaolo Yaumauchi, M.D.
- Start date
- 2018-10-01
- Primary completion
- 2022-01
- Sex
- All
- Age range
- from 21 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Argentina
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion criteria * Pain on the ulnar side of the wrist. * PRWE greater than 40 Exclusion criteria * Radioulnar instability more than moderate as determined by a positive ulna fovea sign or ulna grinding test * Surgery in the wrist area * Infection in the wrist area * Other wrist pathology on examination * Other pain area that is constant, interferes with sleep, or is as bad, or worse, than shoulder pain. * Diabetes or other peripheral neuropathy * Radiculopathy * Unstable psychiatric function. * Current opioid use. * Vulnerable patients * Pregnancy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03411811